[{"id":"cdd2cf51-2554-4888-95bf-15a728fa1c55","acronym":"PYTHON","url":"https://clinicaltrials.gov/study/NCT05885776","created_at":"2023-06-02T14:06:01.965Z","updated_at":"2024-07-02T16:35:46.626Z","phase":"Phase 2","brief_title":"Preoperative Treatment of HR+/HER2+Breast Cancer With Pirotinib, Trastuzumab and AI Research","source_id_and_acronym":"NCT05885776 - PYTHON","lead_sponsor":"Tianjin Medical University Cancer Institute and Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • pirotinib (KBP-5209)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 09/13/2022","start_date":" 09/13/2022","primary_txt":" Primary completion: 03/30/2024","primary_completion_date":" 03/30/2024","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2023-06-02"}]